1
Clinical Trials associated with Autologous Umbilical Cord Blood Cells(ReGen Theranostics)Phase I Safety Study of Autologous Umbilical Cord Blood Derived Mononuclear Cells During Surgical Stage II Palliation of Hypoplastic Left Heart Syndrome
This is a Phase I study to determine the safety and feasibility of injections of autologous umbilical cord blood (UCB) cells into the right ventricle of Hypoplastic Left Heart Syndrome (HLHS) children undergoing a scheduled Glenn surgical procedure.
The investigators are doing this research study to find out if autologous stem cells from the individual's own umbilical cord blood can be used to strengthen the muscle of the right side of their heart. This will help determine the safety and feasibility of using cell-based regenerative therapy as an additional treatment for the management of HLHS.
100 Clinical Results associated with Autologous Umbilical Cord Blood Cells(ReGen Theranostics)
100 Translational Medicine associated with Autologous Umbilical Cord Blood Cells(ReGen Theranostics)
100 Patents (Medical) associated with Autologous Umbilical Cord Blood Cells(ReGen Theranostics)
100 Deals associated with Autologous Umbilical Cord Blood Cells(ReGen Theranostics)